- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Submit data on prevalence and genetic polymorphism of disease: CDSCO Panel Tells Dr Reddy's Laboratories on Siponimod tablet
New Delhi:In response to the proposal presented by the drug major Dr Reddy's Laboratories to manufacture and market the neurodrug Siponimod tablets 0.25 mg, 1 mg, and 2 mg, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined the firm to submit the data on prevalence and the genetic polymorphism of the disease secondary progressive multiple sclerosis.
This came after Dr. Reddy's Laboratories presented a proposal for a grant of permission to manufacture and market new drug Siponimod tablets 0.25 mg, 1 mg, and 2 mg, along with the bioequivalence (BE) study report of higher strength, i.e., 2 mg, and requested a local Phase-III clinical trial waiver and bioequivalence waiver for lower strength before the committee.
Siponimod is in a class of medications called sphingosine l-phosphate receptor modulators. It works by decreasing the action of immune cells that may cause nerve damage.
Siponimod is used to prevent episodes of symptoms and slow the worsening of disability in adults with relapsing-remitting forms (course of disease where symptoms flare up from time to time) of multiple sclerosis (MS), a disease in which the nerves do not function properly and people may experience weakness and numbness.
At the recent SEC meeting for neurology and psychiatry held on June 24, 2024, the expert panel reviewed the proposal presented by the drug major, Dr. Reddy's Laboratories, to manufacture and market the new drug Siponimod tablets (0.25 mg, 1 mg, and 2 mg), along with a BE study report of higher strength, i.e., 2 mg.
After detailed deliberation, the committee noted that:
1. Opinion from the ICMR may be sought regarding the indication under discussion for the proposed new drug Siponimod.2. As there is no complete set of data on the prevalence of the disease and the genetic polymorphism of Secondary Progressive Multiple Sclerosis in the public domain. Hence, the firm should submit the relevant data on prevalence of the disease and the genetic polymorphism of Secondary Progressive Multiple Sclerosis.
In view of the above, the committee recommended that the firm should submit data on the prevalence and the genetic polymorphism of the disease, Secondary Progressive Multiple Sclerosis, for further discussion.
Also Read: Cipla Gets CDSCO Panel Nod to Study Plazomicin Injection
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751